Teng Jun-Jie, Zhang Jian, Zhang Tian-Yi, Zhang Shu, Li Bao-Sheng
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan City, Shandong province, People's Republic of China; School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan City, Shandong province, People's Republic of China.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan City, Shandong province, People's Republic of China.
Onco Targets Ther. 2015 Dec 21;9:37-47. doi: 10.2147/OTT.S94458. eCollection 2016.
Although accumulating evidence suggests peripheral blood lymphocyte-to-monocyte ratio (LMR) could act as a prognosis predictor in various tumors, the prognostic value of LMR still remains controversial. We carried out this meta-analysis to evaluate the association of pretreatment LMR with survival outcomes in patients with solid tumors.
Eligible studies were collected and extracted by searching PubMed and Embase databases up to June 3, 2015. The pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were computed to assess the prognostic value of LMR quantitatively.
Eighteen studies with a total of 8,377 participants were enrolled in this meta-analysis. Our findings indicated that elevated pre-treatment LMR predicted a significantly favorable overall survival (HR=0.59, 95% CI: 0.53-0.67) and disease-free survival (HR=0.74, 95% CI: 0.68-0.80) in solid tumor patients. Subgroup analyses revealed that enhanced LMR was significantly associated with favorable overall survival in patients with digestive system cancers (HR=0.63, 95% CI: 0.49-0.81), urinary tract tumors (HR=0.66, 95% CI: 0.52-0.84), lung cancer (HR=0.62, 95% CI: 0.54-0.72), and nasopharyngeal carcinoma (HR=0.50, 95% CI: 0.43-0.57).
This meta-analysis showed that enhanced LMR may indicate a favorable prognosis in patients with solid tumors.
尽管越来越多的证据表明外周血淋巴细胞与单核细胞比值（LMR）可作为多种肿瘤的预后预测指标，但LMR的预后价值仍存在争议。我们进行了这项荟萃分析，以评估实体瘤患者治疗前LMR与生存结果之间的关联。
通过检索截至2015年6月3日的PubMed和Embase数据库收集并提取符合条件的研究。计算汇总风险比（HR）及其95%置信区间（CI），以定量评估LMR的预后价值。
本荟萃分析纳入了18项研究，共8377名参与者。我们的研究结果表明，实体瘤患者治疗前LMR升高预示着总体生存率（HR=0.59，95%CI：0.53-0.67）和无病生存率（HR=0.74，95%CI：0.68-0.80）显著良好。亚组分析显示，LMR升高与消化系统癌症（HR=0.63，95%CI：0.49-0.81）、泌尿系统肿瘤（HR=0.66，95%CI：0.52-0.84）、肺癌（HR=0.62，95%CI：0.54-0.72）和鼻咽癌（HR=0.50，95%CI：0.43-0.57）患者的良好总体生存率显著相关。
这项荟萃分析表明，LMR升高可能预示实体瘤患者预后良好。
